CO4970819A1 - Tratamiento de disfuncion sexual femenina en una hembra humana - Google Patents

Tratamiento de disfuncion sexual femenina en una hembra humana

Info

Publication number
CO4970819A1
CO4970819A1 CO99005067A CO99005067A CO4970819A1 CO 4970819 A1 CO4970819 A1 CO 4970819A1 CO 99005067 A CO99005067 A CO 99005067A CO 99005067 A CO99005067 A CO 99005067A CO 4970819 A1 CO4970819 A1 CO 4970819A1
Authority
CO
Colombia
Prior art keywords
female
sexual dysfunction
treatment
human
human female
Prior art date
Application number
CO99005067A
Other languages
English (en)
Inventor
El-Rashidy Ragab
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Publication of CO4970819A1 publication Critical patent/CO4970819A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Forma de dosis sublingual para mejorar la disfunción sexual en unahembra humana, que comprende apomorfina o una sal de adición de ácido farmacéuticamente aceptable de la misma en una cantidad suficiente; cuando es administrada a dicha hembra humana, se incrementa el flujo de sangre intraclitoral y el flujo de sangre en la pared vaginal sobre la estimulación de dicha hembra pero menos que la cantidad que induce a náusea sustancial.
CO99005067A 1998-01-30 1999-01-29 Tratamiento de disfuncion sexual femenina en una hembra humana CO4970819A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
CO4970819A1 true CO4970819A1 (es) 2000-11-07

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99005067A CO4970819A1 (es) 1998-01-30 1999-01-29 Tratamiento de disfuncion sexual femenina en una hembra humana

Country Status (34)

Country Link
US (2) US5945117A (es)
EP (1) EP1056419A4 (es)
JP (1) JP2002501875A (es)
KR (1) KR20010040477A (es)
CN (1) CN1250221C (es)
AR (1) AR017976A1 (es)
AU (1) AU752928B2 (es)
BG (1) BG64667B1 (es)
BR (1) BR9908038A (es)
CA (1) CA2322289A1 (es)
CO (1) CO4970819A1 (es)
CR (1) CR5959A (es)
DZ (1) DZ2714A1 (es)
GC (1) GC0000096A (es)
GT (1) GT199900013A (es)
HK (1) HK1040901B (es)
HN (1) HN1999000015A (es)
HU (1) HUP0101268A3 (es)
IL (2) IL137569A0 (es)
JO (1) JO2085B1 (es)
MA (1) MA26600A1 (es)
MX (1) MXPA00007447A (es)
NO (1) NO319821B1 (es)
NZ (1) NZ506597A (es)
PA (1) PA8467801A1 (es)
PE (1) PE20000240A1 (es)
PL (1) PL194350B1 (es)
SK (1) SK11362000A3 (es)
TN (1) TNSN99008A1 (es)
TR (1) TR200002220T2 (es)
TW (1) TW550069B (es)
UY (1) UY25374A1 (es)
WO (1) WO1999038467A1 (es)
ZA (1) ZA99686B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
JP2002518435A (ja) * 1998-06-22 2002-06-25 クイーンズ ユニバーシティ アット キングストン 女性の性機能不全の治療または改善のための方法および組成物
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
WO2001076602A1 (en) * 2000-04-07 2001-10-18 Tap Pharmaceutical Products Inc. Apomorphine derivatives and methods for their use
US6762202B2 (en) 2000-05-09 2004-07-13 Nitromed, Inc. Infrared thermography and methods of use
US6737084B2 (en) 2000-06-27 2004-05-18 Qualilife Compositions and methods for enhancing or treating female sexual response
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
AU2002235129A1 (en) 2000-11-15 2002-05-27 Tap Pharmaceutical Products Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
CZ20031458A3 (cs) * 2000-11-22 2004-02-18 Abbott Laboratories Léčivo pro léčení sexuální dysfunkce savce
JP2004520389A (ja) * 2001-02-08 2004-07-08 ファルマシア・コーポレーション 性的不全の治療のための早期効果発現薬剤
CN1720054A (zh) * 2002-03-19 2006-01-11 布雷恩及比扬德生物科技公司 阿朴吗啡和其类似物的糖苷和原酸酯糖苷衍生物及其用途
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (en) * 2002-10-10 2004-04-10 Queen's University At Kingston Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
CN101227892B (zh) * 2005-04-08 2013-06-05 舌交付有限公司 口腔给药系统
JP2009504628A (ja) * 2005-08-10 2009-02-05 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
EP2233472B1 (en) * 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
DK2442650T3 (en) 2009-06-12 2015-12-07 Cynapsus Therapeutics Inc sublingual apomorphine
WO2011130608A1 (en) * 2010-04-15 2011-10-20 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
US9353067B2 (en) 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
JP7211706B2 (ja) 2015-04-21 2023-01-24 サノヴィオン ファーマシュティカルズ インコーポレーテッド 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0641202A1 (en) * 1992-05-18 1995-03-08 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69534693T2 (de) * 1994-04-22 2006-08-31 Pentech Pharmaceuticals, Inc., Wheeling Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
BG104715A (bg) 2001-02-28
NO20003845D0 (no) 2000-07-27
CN1250221C (zh) 2006-04-12
PL194350B1 (pl) 2007-05-31
PA8467801A1 (es) 2000-09-29
HUP0101268A2 (hu) 2001-09-28
IL137569A (en) 2006-08-01
JP2002501875A (ja) 2002-01-22
NZ506597A (en) 2003-07-25
GC0000096A (en) 2005-06-29
EP1056419A1 (en) 2000-12-06
JO2085B1 (en) 2000-05-21
KR20010040477A (ko) 2001-05-15
NO20003845L (no) 2000-09-28
TW550069B (en) 2003-09-01
CN1313742A (zh) 2001-09-19
US5945117A (en) 1999-08-31
IL137569A0 (en) 2001-07-24
MA26600A1 (fr) 2004-12-20
ZA99686B (en) 1999-07-28
NO319821B1 (no) 2005-09-19
HK1040901A1 (en) 2002-06-28
EP1056419A4 (en) 2007-05-02
PL342062A1 (en) 2001-05-21
UY25374A1 (es) 1999-09-27
CR5959A (es) 1999-07-28
GT199900013A (es) 2001-07-20
TNSN99008A1 (fr) 2005-11-10
US6193992B1 (en) 2001-02-27
BG64667B1 (bg) 2005-11-30
BR9908038A (pt) 2002-01-02
TR200002220T2 (tr) 2000-12-21
HK1040901B (zh) 2006-11-24
SK11362000A3 (sk) 2001-02-12
DZ2714A1 (fr) 2003-09-01
AU752928B2 (en) 2002-10-03
AU2564499A (en) 1999-08-16
HN1999000015A (es) 1999-08-23
CA2322289A1 (en) 1999-08-05
WO1999038467A1 (en) 1999-08-05
HUP0101268A3 (en) 2002-12-28
AR017976A1 (es) 2001-10-24
MXPA00007447A (es) 2006-01-25
PE20000240A1 (es) 2000-03-31

Similar Documents

Publication Publication Date Title
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
NO20014519L (no) Apomorfin- og sildenafilpreparat
NO2012015I2 (no) Dapoxetine
NZ545130A (en) Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
AR041725A1 (es) Prevencion, tratamiento de la enfermedad sinucleinopatica y composicion farmacologica
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AR041069A1 (es) Composicion de tolterodina liquida oral
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
AR022338A1 (es) Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
CN1092059C (zh) 一种治疗弓形虫病的药物
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
JP2005519919A5 (es)
SE9700617D0 (sv) New composition
RU2002122703A (ru) Способ лечения воспалительных и воспалительно-деструктивных заболеваний пародонта
RU2002112882A (ru) Способ повышения резистентности сухостойных коров
ES2189639A1 (es) Composicion acuosa que contiene acido acetilsalicilico
RU2002118801A (ru) Способ профилактики катетер-ассоциированных инфекций
RU2001112719A (ru) Способ лечения стенокардии и алекситимии у больных пожилого возраста
ES2062752T3 (es) Preparado de una sal de oxipurinol en forma oral para el tratamiento de hiperuricemia.
AR004157A1 (es) Sal del tipo 2'-onio de paclitaxel soluble en agua, metodo de preparacion y uso de la misma y forma de dosificacion que la contiene.